CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

Released Friday, 13th June 2025
Good episode? Give it some love!
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

Friday, 13th June 2025
Good episode? Give it some love!
Rate Episode
List

A conversation with Ben Fairfax about the recent article: CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. This episode discusses Milotay, G., Little, M., Watson, R.A. et al. CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. Nat Med (2025). https://doi.org/10.1038/s41591-025-03647-1.

Show More